OncoMatch/Clinical Trials/NCT06514313
Clinical Trial of VIM With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma.
Is NCT06514313 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Mitoxantrone Hydrochloride Liposome+Irinotecan+Vincristine and Temozolomide+Irinotecan+Vincristine for soft tissue sarcoma.
Treatment: Mitoxantrone Hydrochloride Liposome+Irinotecan+Vincristine · Temozolomide+Irinotecan+Vincristine — Explore the efficacy and safety of mitoxantrone liposome combined with irinotecan and vincristine (VIM) in the treatment of relapsed/refractory soft tissue sarcoma in children.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Sarcoma
Demographics
Prior therapy
Cannot have received: anthracycline (mitoxantrone, mitoxantrone liposomes, adriamycin)
Exception: adriamycin cumulative dose ≤ 360 mg/m^2 and no cardiac disease caused by anthracyclines
Once received mitoxantrone or mitoxantrone liposomes. Previous treatment with adriamycin or other anthracyclines with a total cumulative dose of adriamycin > 360 mg/m^2; Or patients with cardiac disease caused by previous anthracyclines.
Cannot have received: VIT chemotherapy (irinotecan, temozolomide, vincristine)
Patients who had received previous VIT (irinotecan + temozolomide + vincristine) chemotherapy.
Lab requirements
Blood counts
Good blood and organ function.
Kidney function
Good blood and organ function.
Liver function
Good blood and organ function.
Cardiac function
LVEF ≥ 50% by cardiac COLOR ultrasound; ECG suggests no myocardial ischemia; no history of arrhythmia requiring drug intervention before enrollment.
Heart function: a) Cardiac COLOR ultrasound detection LVEF≥ 50%; b) ECG suggests no myocardial ischemia; c) No history of arrhythmia requiring drug intervention before enrollment. Good blood and organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06514313 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anthracycline, VIT chemotherapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 21 years or younger and at least 2 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages